419 related articles for article (PubMed ID: 32306833)
1. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
2. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
4. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
Beck A; Reichert JM
MAbs; 2013; 5(5):621-3. PubMed ID: 23924791
[TBL] [Abstract][Full Text] [Related]
5. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
[TBL] [Abstract][Full Text] [Related]
6. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
7. Current Japanese Regulatory Systems for Generics and Biosimilars.
Kuribayashi R; Sawanobori K
J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
[TBL] [Abstract][Full Text] [Related]
8. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
9. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
Busse A; Lüftner D
Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar monoclonal antibodies: Challenges and approaches towards formulation.
Goli VAR; Butreddy A
Chem Biol Interact; 2022 Oct; 366():110116. PubMed ID: 36007632
[TBL] [Abstract][Full Text] [Related]
11. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
Williamson R; Munro T; Ascher D; Robertson A; Pregelj L
Value Health; 2024 Mar; 27(3):287-293. PubMed ID: 38141814
[TBL] [Abstract][Full Text] [Related]
12. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
13. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
Mellstedt H
Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
[TBL] [Abstract][Full Text] [Related]
14. Sample Size for Biosimilar Trials: In Defense of Synthesis.
Clark T; Jo SJ; Phillips A
Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
[TBL] [Abstract][Full Text] [Related]
15. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
16. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: impact of differences with Hatch-Waxman.
Kowalchyk K; Crowley-Weber C
Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar monoclonal antibodies in China: A patent review.
Liu JW; Yang YH; Wu N; Wei JF
Bioengineered; 2022 Jun; 13(6):14503-14518. PubMed ID: 35758066
[TBL] [Abstract][Full Text] [Related]
20. Rituximab biosimilars.
Vital EM; Kay J; Emery P
Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]